GlassScriptPhysician profile
Richard M Lee
NPI 1033118229
$8,253.81
in general payments reported to CMS, 2019-2025
36 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $2,474 · 2021: $1,911 · 2022: $416 · 2023: $450 · 2024: $1,931 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,593 · Food and Beverage: $1,062 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,592.50 |
| Food and Beverage | $1,062.03 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,915.91 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $1,300.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $490.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $284.10 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $252.21 | 2019-2025 | |
| Incyte Corporation | $247.89 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $196.68 | 2019-2024 | Krazati |
| Genentech USA, INC. | $158.84 | 2019-2024 | Phesgo |
| Janssen Biotech, INC. | $125.39 | 2023 | Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $114.63 | 2019 | |
| Emd Serono, INC. | $108.01 | 2019-2023 | Tepmetko |
| Clovis Oncology, INC. | $99.95 | 2019 | |
| Daiichi Sankyo INC. | $78.34 | 2023-2025 | Enhertu, Vanflyta |
| Genzyme Corporation | $77.49 | 2024-2025 | |
| Seagen INC. | $70.85 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $70.81 | 2021-2022 | |
| Global Blood Therapeutics, INC. | $69.08 | 2021 | |
| Myriad Genetic Laboratories, INC. | $54.45 | 2021-2023 | Myrisk |
| Pharmacyclics LLC, An Abbvie Company | $52.48 | 2019 | |
| Menarini Silicon Biosystems, INC. | $50.30 | 2024-2025 | |
| Astellas Pharma US INC | $42.98 | 2024-2025 | Vyloy |
| Kyowa Kirin, INC. | $42.68 | 2021-2022 | |
| Glaxosmithkline, LLC. | $39.98 | 2023-2024 | Ojjaara, Trelegy Ellipta, Shingrix |
| Array Biopharma INC | $38.02 | 2019 | |
| Gilead Sciences, INC. | $33.51 | 2021 | |
| Sumitomo Pharma America, INC. | $32.43 | 2023-2024 | Orgovyx |
| Tersera Therapeutics LLC | $27.02 | 2025 | Xermelo |
| Blueprint Medicines Corporation | $24.99 | 2020 | |
| Ge Healthcare | $24.35 | 2022 | |
| Amgen INC. | $22.49 | 2022 | |
| Celgene Corporation | $21.84 | 2023 | Reblozyl |
| Cti Biopharma Corp. | $21.01 | 2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $20.21 | 2022 | |
| Telix Pharmaceuticals | $16.36 | 2024 | Illuccix |
| Helsinn Therapeutics (U.S.), INC. | $14.07 | 2019 | |
| Tempus Ai, INC | $13.92 | 2024 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.